9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase

Several 9-(phosphonoalkyl)guanines (Gua(CH 2) n CH 2-PO 3H 2; n = 4–6) and 9-(difluorophosphonoalkyl)guanines (Gua(CH 2) n CF 2PO 3H 2; n = 3–7) were studied as potential substrates and inhibitors of guanylate kinase. These compounds are inhibitors of the enzyme except 9-(5-phosphonopentyl)guanine (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of biochemistry and biophysics 1992-06, Vol.295 (2), p.253-257
Hauptverfasser: Navé, Jean-François, Eschbach, Anne, Halazy, Serge
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 257
container_issue 2
container_start_page 253
container_title Archives of biochemistry and biophysics
container_volume 295
creator Navé, Jean-François
Eschbach, Anne
Halazy, Serge
description Several 9-(phosphonoalkyl)guanines (Gua(CH 2) n CH 2-PO 3H 2; n = 4–6) and 9-(difluorophosphonoalkyl)guanines (Gua(CH 2) n CF 2PO 3H 2; n = 3–7) were studied as potential substrates and inhibitors of guanylate kinase. These compounds are inhibitors of the enzyme except 9-(5-phosphonopentyl)guanine ( n = 4) which is a substrate with an efficiency of phosphorylation of about 0.3% that of GMP, as estimated from the V max K m ratios. The phosphonate and difluorophosphonate derivatives with n = 5 produce optimal inhibition. These two compounds have similar affinity, both being competitive inhibitors with respect to GMP and noncompetitive inhibitors with respect to ATP. pH-dependence studies indicate that the dianionic rather than the monoanionic form of these compounds bind to the enzyme. The lack of phosphorylation of 9-(5,5-difluoro-5-phosphonopentyl)guanine by guanylate kinase is explained by the decreased nucleophilic character of the oxygen atoms of the phosphonate group rather than by inadequate binding to the GMP-binding site.
doi_str_mv 10.1016/0003-9861(92)90515-X
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72950706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000398619290515X</els_id><sourcerecordid>72950706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-9f1881cc850f99c690184de36f12555f9e911cbb3b55162cace650da160932c13</originalsourceid><addsrcrecordid>eNqFkMFq3DAQhkVpSLdp36AFH0pJDm5mbEuWLoUS2iYQSA8J5CZkedxV47W2Gnth377e7JLektMw_N8_DJ8QHxC-IKA6B4AyN1rhqSnODEiU-f0rsUAwKodSV6_F4gl5I94y_wFArFRxLI6xRFWXciHuTH76axl5vYxDdP3Dtj_7PbkhDJS1lMLGjWFDnDnOeGp4TG6ct5iyMCxDE8aY5q3LdpVtP2fZQxgc0ztx1Lme6f1hnoi7H99vLy7z65ufVxffrnNfYT3mpkOt0XstoTPGKwOoq5ZK1WEhpewMGUTfNGUjJarCO09KQutQgSkLj-WJ-Ly_u07x70Q82lVgT33vBooT27owEmpQL4KoKtD4CFZ70KfInKiz6xRWLm0tgt1ptzundufUmsI-arf3c-3j4f7UrKj9X9p7nvNPh9yxd32X3OADP2Gy0nWNesa-7jGapW0CJcs-0OCpDYn8aNsYnv_jH-V8njA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16408106</pqid></control><display><type>article</type><title>9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Navé, Jean-François ; Eschbach, Anne ; Halazy, Serge</creator><creatorcontrib>Navé, Jean-François ; Eschbach, Anne ; Halazy, Serge</creatorcontrib><description>Several 9-(phosphonoalkyl)guanines (Gua(CH 2) n CH 2-PO 3H 2; n = 4–6) and 9-(difluorophosphonoalkyl)guanines (Gua(CH 2) n CF 2PO 3H 2; n = 3–7) were studied as potential substrates and inhibitors of guanylate kinase. These compounds are inhibitors of the enzyme except 9-(5-phosphonopentyl)guanine ( n = 4) which is a substrate with an efficiency of phosphorylation of about 0.3% that of GMP, as estimated from the V max K m ratios. The phosphonate and difluorophosphonate derivatives with n = 5 produce optimal inhibition. These two compounds have similar affinity, both being competitive inhibitors with respect to GMP and noncompetitive inhibitors with respect to ATP. pH-dependence studies indicate that the dianionic rather than the monoanionic form of these compounds bind to the enzyme. The lack of phosphorylation of 9-(5,5-difluoro-5-phosphonopentyl)guanine by guanylate kinase is explained by the decreased nucleophilic character of the oxygen atoms of the phosphonate group rather than by inadequate binding to the GMP-binding site.</description><identifier>ISSN: 0003-9861</identifier><identifier>EISSN: 1096-0384</identifier><identifier>DOI: 10.1016/0003-9861(92)90515-X</identifier><identifier>PMID: 1316735</identifier><identifier>CODEN: ABBIA4</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>9-(phosphonoalkyl)guanine ; Adenosine Triphosphate - metabolism ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Binding Sites ; Biological and medical sciences ; derivatives ; enzymatic activity ; Guanine - analogs &amp; derivatives ; Guanine - metabolism ; Guanine - pharmacology ; Guanosine Monophosphate - metabolism ; guanylate kinase ; Guanylate Kinases ; Hydrogen-Ion Concentration ; Kinetics ; Medical sciences ; Nucleoside-Phosphate Kinase - antagonists &amp; inhibitors ; Nucleoside-Phosphate Kinase - metabolism ; Organophosphorus Compounds - metabolism ; Organophosphorus Compounds - pharmacology ; Pharmacology. Drug treatments ; Substrate Specificity ; substrates</subject><ispartof>Archives of biochemistry and biophysics, 1992-06, Vol.295 (2), p.253-257</ispartof><rights>1992</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-9f1881cc850f99c690184de36f12555f9e911cbb3b55162cace650da160932c13</citedby><cites>FETCH-LOGICAL-c417t-9f1881cc850f99c690184de36f12555f9e911cbb3b55162cace650da160932c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/000398619290515X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5487718$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1316735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navé, Jean-François</creatorcontrib><creatorcontrib>Eschbach, Anne</creatorcontrib><creatorcontrib>Halazy, Serge</creatorcontrib><title>9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase</title><title>Archives of biochemistry and biophysics</title><addtitle>Arch Biochem Biophys</addtitle><description>Several 9-(phosphonoalkyl)guanines (Gua(CH 2) n CH 2-PO 3H 2; n = 4–6) and 9-(difluorophosphonoalkyl)guanines (Gua(CH 2) n CF 2PO 3H 2; n = 3–7) were studied as potential substrates and inhibitors of guanylate kinase. These compounds are inhibitors of the enzyme except 9-(5-phosphonopentyl)guanine ( n = 4) which is a substrate with an efficiency of phosphorylation of about 0.3% that of GMP, as estimated from the V max K m ratios. The phosphonate and difluorophosphonate derivatives with n = 5 produce optimal inhibition. These two compounds have similar affinity, both being competitive inhibitors with respect to GMP and noncompetitive inhibitors with respect to ATP. pH-dependence studies indicate that the dianionic rather than the monoanionic form of these compounds bind to the enzyme. The lack of phosphorylation of 9-(5,5-difluoro-5-phosphonopentyl)guanine by guanylate kinase is explained by the decreased nucleophilic character of the oxygen atoms of the phosphonate group rather than by inadequate binding to the GMP-binding site.</description><subject>9-(phosphonoalkyl)guanine</subject><subject>Adenosine Triphosphate - metabolism</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>derivatives</subject><subject>enzymatic activity</subject><subject>Guanine - analogs &amp; derivatives</subject><subject>Guanine - metabolism</subject><subject>Guanine - pharmacology</subject><subject>Guanosine Monophosphate - metabolism</subject><subject>guanylate kinase</subject><subject>Guanylate Kinases</subject><subject>Hydrogen-Ion Concentration</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Nucleoside-Phosphate Kinase - antagonists &amp; inhibitors</subject><subject>Nucleoside-Phosphate Kinase - metabolism</subject><subject>Organophosphorus Compounds - metabolism</subject><subject>Organophosphorus Compounds - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Substrate Specificity</subject><subject>substrates</subject><issn>0003-9861</issn><issn>1096-0384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFq3DAQhkVpSLdp36AFH0pJDm5mbEuWLoUS2iYQSA8J5CZkedxV47W2Gnth377e7JLektMw_N8_DJ8QHxC-IKA6B4AyN1rhqSnODEiU-f0rsUAwKodSV6_F4gl5I94y_wFArFRxLI6xRFWXciHuTH76axl5vYxDdP3Dtj_7PbkhDJS1lMLGjWFDnDnOeGp4TG6ct5iyMCxDE8aY5q3LdpVtP2fZQxgc0ztx1Lme6f1hnoi7H99vLy7z65ufVxffrnNfYT3mpkOt0XstoTPGKwOoq5ZK1WEhpewMGUTfNGUjJarCO09KQutQgSkLj-WJ-Ly_u07x70Q82lVgT33vBooT27owEmpQL4KoKtD4CFZ70KfInKiz6xRWLm0tgt1ptzundufUmsI-arf3c-3j4f7UrKj9X9p7nvNPh9yxd32X3OADP2Gy0nWNesa-7jGapW0CJcs-0OCpDYn8aNsYnv_jH-V8njA</recordid><startdate>19920601</startdate><enddate>19920601</enddate><creator>Navé, Jean-François</creator><creator>Eschbach, Anne</creator><creator>Halazy, Serge</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M81</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19920601</creationdate><title>9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase</title><author>Navé, Jean-François ; Eschbach, Anne ; Halazy, Serge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-9f1881cc850f99c690184de36f12555f9e911cbb3b55162cace650da160932c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>9-(phosphonoalkyl)guanine</topic><topic>Adenosine Triphosphate - metabolism</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>derivatives</topic><topic>enzymatic activity</topic><topic>Guanine - analogs &amp; derivatives</topic><topic>Guanine - metabolism</topic><topic>Guanine - pharmacology</topic><topic>Guanosine Monophosphate - metabolism</topic><topic>guanylate kinase</topic><topic>Guanylate Kinases</topic><topic>Hydrogen-Ion Concentration</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Nucleoside-Phosphate Kinase - antagonists &amp; inhibitors</topic><topic>Nucleoside-Phosphate Kinase - metabolism</topic><topic>Organophosphorus Compounds - metabolism</topic><topic>Organophosphorus Compounds - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Substrate Specificity</topic><topic>substrates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navé, Jean-François</creatorcontrib><creatorcontrib>Eschbach, Anne</creatorcontrib><creatorcontrib>Halazy, Serge</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 3</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of biochemistry and biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navé, Jean-François</au><au>Eschbach, Anne</au><au>Halazy, Serge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase</atitle><jtitle>Archives of biochemistry and biophysics</jtitle><addtitle>Arch Biochem Biophys</addtitle><date>1992-06-01</date><risdate>1992</risdate><volume>295</volume><issue>2</issue><spage>253</spage><epage>257</epage><pages>253-257</pages><issn>0003-9861</issn><eissn>1096-0384</eissn><coden>ABBIA4</coden><abstract>Several 9-(phosphonoalkyl)guanines (Gua(CH 2) n CH 2-PO 3H 2; n = 4–6) and 9-(difluorophosphonoalkyl)guanines (Gua(CH 2) n CF 2PO 3H 2; n = 3–7) were studied as potential substrates and inhibitors of guanylate kinase. These compounds are inhibitors of the enzyme except 9-(5-phosphonopentyl)guanine ( n = 4) which is a substrate with an efficiency of phosphorylation of about 0.3% that of GMP, as estimated from the V max K m ratios. The phosphonate and difluorophosphonate derivatives with n = 5 produce optimal inhibition. These two compounds have similar affinity, both being competitive inhibitors with respect to GMP and noncompetitive inhibitors with respect to ATP. pH-dependence studies indicate that the dianionic rather than the monoanionic form of these compounds bind to the enzyme. The lack of phosphorylation of 9-(5,5-difluoro-5-phosphonopentyl)guanine by guanylate kinase is explained by the decreased nucleophilic character of the oxygen atoms of the phosphonate group rather than by inadequate binding to the GMP-binding site.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>1316735</pmid><doi>10.1016/0003-9861(92)90515-X</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-9861
ispartof Archives of biochemistry and biophysics, 1992-06, Vol.295 (2), p.253-257
issn 0003-9861
1096-0384
language eng
recordid cdi_proquest_miscellaneous_72950706
source MEDLINE; Elsevier ScienceDirect Journals
subjects 9-(phosphonoalkyl)guanine
Adenosine Triphosphate - metabolism
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Binding Sites
Biological and medical sciences
derivatives
enzymatic activity
Guanine - analogs & derivatives
Guanine - metabolism
Guanine - pharmacology
Guanosine Monophosphate - metabolism
guanylate kinase
Guanylate Kinases
Hydrogen-Ion Concentration
Kinetics
Medical sciences
Nucleoside-Phosphate Kinase - antagonists & inhibitors
Nucleoside-Phosphate Kinase - metabolism
Organophosphorus Compounds - metabolism
Organophosphorus Compounds - pharmacology
Pharmacology. Drug treatments
Substrate Specificity
substrates
title 9-(Phosphonoalkyl)guanine derivatives as substrates or inhibitors of guanylate kinase
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A42%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=9-(Phosphonoalkyl)guanine%20derivatives%20as%20substrates%20or%20inhibitors%20of%20guanylate%20kinase&rft.jtitle=Archives%20of%20biochemistry%20and%20biophysics&rft.au=Nav%C3%A9,%20Jean-Fran%C3%A7ois&rft.date=1992-06-01&rft.volume=295&rft.issue=2&rft.spage=253&rft.epage=257&rft.pages=253-257&rft.issn=0003-9861&rft.eissn=1096-0384&rft.coden=ABBIA4&rft_id=info:doi/10.1016/0003-9861(92)90515-X&rft_dat=%3Cproquest_cross%3E72950706%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16408106&rft_id=info:pmid/1316735&rft_els_id=000398619290515X&rfr_iscdi=true